{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:43:21Z","timestamp":1793065401623,"version":"4.5.0"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>To investigate the 2-year healing rate of macular edema (ME) secondary to branch retinal vein occlusion (BRVO) treated initially with intravitreal ranibizumab (IVR) and later combined with other treatment as needed, and the characteristics of refractory cases.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>130 patients (130 eyes) with BRVO-ME who received IVR initially were studied. Anti-vascular endothelial growth factor drug was additionally administered when ME relapsed or persisted. Photocoagulation was performed when the non-perfusion area (NPA) was \u22655 disc diameter (DD), and\/or when ME relapsed due to microaneurysm. Patients were classified into a healed group [ME resolved in &lt;2 years or mild ME remained without best-corrected visual acuity (BCVA) loss for \u22656 months] or refractory group (ME persisted for \u22652 years).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>110 eyes were classified into the healed group, and 20 eyes into the refractory group. The healed group and refractory group had, respectively, mean follow-up periods of 21.2 and 37.4 months, and frequencies of NPA \u22655 DD of 55.5 and 25.0% (p = 0.015). In the healed group, mean BCVA (logMAR) improved significantly compared to baseline in all the periods until 24 months after treatment initiation and at the last visit (p&lt;0.001). In the refractory group, mean BCVA improved significantly compared to baseline until 12 months after treatment initiation (p&lt;0.05 for all periods), but was not significantly different at 18 or 24 months or at the last visit.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In patients with BRVO-ME treated initially with IVR and later given additional treatments as needed, the healing rate was 84.6%. In eyes that healed within 2 years, BCVA improved relative to baseline throughout 24 months and at the last visit. In refractory eyes, BCVA improved only until 12 months, and thereafter deteriorated to baseline level at the last examination.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0278968","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T18:31:16Z","timestamp":1672770676000},"page":"e0278968","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Healing rate of macular edema secondary to branch retinal vein occlusion in two years after initiation of intravitreal ranibizumab later combined with other treatment as needed and characteristics of refractory cases"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4755-7813","authenticated-orcid":true,"given":"Setsuko","family":"Kawakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Umazume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"pone.0278968.ref001","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10384-019-00685-4","article-title":"Current practice in the management of branch retinal vein occlusion in Japan: Survey results of retina specialists in Japan","volume":"63","author":"Y Ogura","year":"2019","journal-title":"Jpn J Ophthalmol"},{"key":"pone.0278968.ref002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/archopht.1986.01050130044017","article-title":"Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial","volume":"104","author":"The Branch Vein Occlusion Study Group","year":"1986","journal-title":"Arch Ophthalmol"},{"key":"pone.0278968.ref003","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Longterm outcomes in patients with retinal vein occlusion treated with ranibizumab. The RETAIN Study","volume":"121","author":"PA Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"pone.0278968.ref004","first-page":"39","article-title":"Relationship between grades of macular perfusion and foveal thickness in branch retinal vein occlusion","volume":"7","author":"S Sakimoto","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"pone.0278968.ref005","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1167\/iovs.17-21447","article-title":"Gap in capillary perfusion on optic coherence tomography angiography associated with persistent macular edema in branch retinal vein occlusion","volume":"58","author":"K Tsuboi","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"pone.0278968.ref006","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1167\/iovs.17-23437","article-title":"Changes in retinal microvasculature and visual acuity after anti vascular endothelial growth factor therapy in retinal vein occlusion","volume":"59","author":"A Winegarner","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"pone.0278968.ref007","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1038\/s41598-019-42982-5","article-title":"Branch retinal vein occlusion: treatment outcomes according to the retinal nonperfusion area, clinical subtype, and crossing pattern","volume":"9","author":"Y Iida-Miwa","year":"2019","journal-title":"Sci Rep"},{"key":"pone.0278968.ref008","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.ophtha.2015.04.006","article-title":"Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial","volume":"122","author":"PA Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"key":"pone.0278968.ref009","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"LP Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"pone.0278968.ref010","doi-asserted-by":"crossref","first-page":"29445","DOI":"10.1038\/srep29445","article-title":"Microaneurysms cause refractory macular edema in branch retinal vein occlusion","volume":"6","author":"T Tomiyasu","year":"2016","journal-title":"Sci Rep"},{"key":"pone.0278968.ref011","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/IAE.0000000000001703","article-title":"Clinical findings of eyes with macular edema associated with branch retinal vein occlusion refractory to ranibizumab","volume":"38","author":"T Hasegawa","year":"2018","journal-title":"Retina"},{"key":"pone.0278968.ref012","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s10384-016-0425-5","article-title":"Effect of leaking capillaries and microaneurysms in the perifoveal capillary network on resolution of macular edema by anti-vascular endothelial growth factor treatment","volume":"60","author":"Y Iesato","year":"2016","journal-title":"Jpn J Ophthalmol"},{"key":"pone.0278968.ref013","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","article-title":"Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER Study","volume":"124","author":"R Tadayoni","year":"2017","journal-title":"Ophthalmology"},{"key":"pone.0278968.ref014","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41598-020-79051-1","article-title":"The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-na\u00efve patients","volume":"11","author":"T Murata","year":"2021","journal-title":"Sci Rep"},{"key":"pone.0278968.ref015","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2147\/OPTH.S66878","article-title":"Direct photocoagulation to leakage points to treat chronic macular edema associated with branch retinal vein occlusion: a pilot study","volume":"8","author":"S Sakimoto","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"pone.0278968.ref016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000310354","article-title":"Argon laser scatter photocoagulation in treatment of branch retinal vein occlusion. A prospective clinical trial","volume":"206","author":"SS Hayreh","year":"1993","journal-title":"Ophthalmologica"},{"key":"pone.0278968.ref017","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema","volume":"68","author":"A Kelkar","year":"2020","journal-title":"Indian J Ophthalmol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T18:31:30Z","timestamp":1672770690000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278968"}},"subtitle":[],"editor":[{"given":"Daisuke","family":"Nagasato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0278968","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]}}}